Aptus Capital Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.1M Buy
71,074
+65,480
+1,171% +$3.03M 0.02% 461
2026
Q2
$239K Sell
5,594
-1,628
-23% -$88.4K ﹤0.01% 1043
2026
Q1
$453K Sell
7,222
-70,813
-91% -$5.66M ﹤0.01% 741
2025
Q4
$7.44M Buy
78,035
+2,173
+3% +$213K 0.05% 263
2025
Q3
$7.41M Buy
75,862
+63,382
+508% +$6.56M 0.05% 255
2025
Q2
$1.34M Buy
12,480
+1,098
+10% +$111K 0.01% 479
2025
Q1
$1.15M Sell
11,382
-310
-3% -$31.2K 0.01% 485
2024
Q4
$1.04M Buy
11,692
+1,723
+17% +$152K 0.01% 495
2024
Q3
$835K Buy
9,969
+520
+6% +$41K 0.01% 444
2024
Q2
$728K Buy
9,449
+1,639
+21% +$120K 0.01% 440
2024
Q1
$535K Buy
7,810
+1,149
+17% +$73.9K 0.01% 499
2023
Q4
$385K Buy
6,661
+142
+2% +$7.58K 0.01% 426
2023
Q3
$344K Buy
+6,519
New +$342K 0.01% 447
2022
Q4
– Sell
-64,563
Closed -$2.5M – 805
2022
Q3
$2.5M Sell
64,563
-23,683
-27% -$950K 0.06% 184
2022
Q2
$3.29M Sell
88,246
-490
-0.6% -$19.9K 0.09% 132
2022
Q1
$3.93M Buy
+88,736
New +$3.85M 0.1% 118
2019
Q2
– Sell
-68,767
Closed -$2.64M – 337
2019
Q1
$2.64M Buy
+68,767
New +$2.63M 0.45% 41

Other funds holding BSX

Aptus Capital Advisors's BSX Position: Q3 2026 in Review

Aptus Capital Advisors increased its Boston Scientific (BSX) stake by 1,171% in Q3 2026, buying an estimated $3.03M and bringing the position to 71,074 shares worth $3.1M. The position accounts for 0.02% of the portfolio, ranked #461.

Aptus Capital Advisors first reported a position in BSX in Q1 2019 and has held it in 17 quarters since. The position peaked at $7.44M in Q4 2025. 1,515 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • Aptus Capital Advisors held 71,074 shares of Boston Scientific worth $3.1M as of Q3 2026.
  • Aptus Capital Advisors bought 65,480 Boston Scientific shares in Q3 2026, an estimated $3.03M.
  • Boston Scientific made up 0.02% of Aptus Capital Advisors's portfolio in Q3 2026, its #461 holding.
  • Aptus Capital Advisors first reported a position in Boston Scientific in Q1 2019 and has held it in 17 quarters since.
  • Aptus Capital Advisors's Boston Scientific position peaked at $7.44M in Q4 2025.
  • 1,515 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.